Site Specific and Global Epigenomic Editing
Academic Press Inc (Verlag)
978-0-12-819398-3 (ISBN)
- Noch nicht erschienen (ca. Juni 2025)
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Included protocols and applied case studies examine early disease targets and likely pathways of therapeutic significance while also outlining common challenges in the field. The book addresses its topic in a comprehensive, but accessible manner, highlighting practical tools and burning questions remaining in the field to enable fresh research.
Dr. Feng C. Zhou is Professor Emertus of Anatomy and Cell Biology at Indiana University School of Medicine, Indianapolis, Indiana. In his research, Dr. Zhou studies genetic contributions to gene expression that underpin the neurochemical and neuroanatomical differences contributing to alcohol addiction. His previous research has demonstrated that alcohol alters expression cohorts of neural specification genes, and cell cycling genes in the canonical developmental pathways. In recent years, Dr. Zhou has expanded his research to include the genomics and epigenetics of alcoholism, epigenetic editing by optogenetics, cell-wide DNA de-methylation and re-methylation of purkinje neurons in the developing cerebellum, and environmental alterations of epigenetics prior to the birth, among other topics. Dr. Zhou has published widely in scientific, peer reviewed journals including Scientific Reports, PLoS ONE, Oncotarget, Frontiers in Genetics, Brain Research, Cell Transplantation, and Alcohol. Dr. Tollefsbol is a Distinguished Professor of Biology and a Senior Scientist in the O’Neal Comprehensive Cancer Center, Integrative Center for Aging Research, Nutrition Obesity Research Center, University Wide Microbiome Center, and the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB). He is Director of the UAB Cell Senescence Culture Facility which he established in 1999. Dr. Tollefsbol trained as a Postdoctoral Fellow and Assistant Research Professor with members of the National Academy of Science at Duke University and the University of North Carolina. He earned doctorates in molecular biology and osteopathic medicine from the University of North Texas Health Sciences Center and his bachelor’s degree in Biology from the University of Houston. He has received prior funding from the NCI, NHLBI, NIMH and other federal institutes as well as the Glenn Foundation for Medical Research, Susan G. Komen for the Cure, the American Federation for Aging Research (AFAR), and the American Institute for Cancer Research (AICR) among many other sources.
Part I EPIGENETICS AND EPIGENOMICS
1. Epigenetic editing: Progress and Challenges
2. Epigenetic dynamics: Normal progression and abnormal alteration
3. Epigenomic landscape
4. Histone coding and its compounding influence on gene expression
5. microRNA as a tool for gene regulation
6. RNA editing and genetic influence
7. Epitranscription: Scope and engineering ability
Part II GLOBAL EPIGENETIC EDITING
8. Global epigenetic editing uses methods of DNA methylation alteration drugs
9. Regulating DNA methylation for developmental disorders
10. Histone modification drug the HDACi: Selectivity and promise
11. Histone modification in cancer treatment
12. Alteration of DNA Methylation in gastric cancer
13. Epigenetic therapy for the treatment of epithelial ovarian cancer
14. Epigenetic application on allergy treatment
15. HDACi therapy for the treatment of depression
16. Histone modification on neurodevelopmental and neuropsychiatric disorders
17. Epigenetics and Addiction
18. Epigenetic Treatment of Persistent Viral Infections
19. MicroRNA as strategy of gene regulation
Part III SITE SPECIFIC EPIGENETIC EDITING
20. Strategy and Molecular tools for site-specific editing
21. Site-specific recruitment of epigenetic factors for spatio-temporal epigenetic editing.
22. Monitoring CRISPR-Cas9 mediated DNA-methylation-editing
23. Locus-specific editing of histone modifications
24. Functional DNA methylation and epigenetic editing on proneuron genes during neuroglial differentiation
25. Epigenetic editing through regulating CRISPR-Cas9 mediated non-coding RNA
26. Epigenetic editing targeting a parkinsonian gene
27. Cancer gene epigenetic editing
28. Epigenetic editing to unveil epigenetic mechanism of breast cancer
29. Editing DNA Methylation on Fragile X syndrome
30. Can RNA editing be engineered?
31. Genetic and epigenetic interactive approaches
Part IV TRANSLATIONAL AND CLINIC APPLICATION
32. Tuning DNA methylation in treating breast cancer:
33. Imminent Epigenetic editing in cancer treatment
34. Epigenetic editing for developmental disorders
35. Epigenetic editing on genetic imprinting
36. Prospective epigenetic treatment on Neurological disease
37. Epigenetic alterations and personalized treatment in cancer
Part V CLOSING VIEW
38. Obstacles and prospective of changing epigenetic codes
39. Ethical matters in modification of epigenetic codes
40. Future epigenetic treatment
| Erscheint lt. Verlag | 1.6.2025 |
|---|---|
| Reihe/Serie | Translational Epigenetics |
| Mitarbeit |
Herausgeber (Serie): Trygve Tollefsbol |
| Verlagsort | San Diego |
| Sprache | englisch |
| Maße | 191 x 235 mm |
| Themenwelt | Informatik ► Weitere Themen ► Bioinformatik |
| Studium ► 2. Studienabschnitt (Klinik) ► Humangenetik | |
| Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie | |
| ISBN-10 | 0-12-819398-0 / 0128193980 |
| ISBN-13 | 978-0-12-819398-3 / 9780128193983 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
